Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry incorrectly groups three distinct molecular targets: Caspase-3, Bad, and Bax. Caspase-3 is a cysteine-aspartic protease and key executioner in apoptosis. Bad is a pro-apoptotic BH3-only protein that antagonizes anti-apoptotic Bcl-2 proteins. Bax is a key pro-apoptotic Bcl-2 family member that facilitates mitochondrial outer membrane permeabilization. While all three are involved in the apoptosis pathway and are recognized therapeutic targets, they represent independent gene products, structures, specific functions, and have distinct therapeutic implications. They should be catalogued individually for biomedical or drug discovery purposes.
This entry comprises three distinct proteins with varied mechanisms of action. Caspase-3 acts as an executioner protease leading to programmed cell death. BAD promotes apoptosis by neutralizing anti-apoptotic Bcl-2 proteins. BAX promotes mitochondrial permeabilization and cytochrome c release, leading to caspase activation. Each plays a distinct role within the apoptosis pathway.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Caspase-3, Bad, Bax (N/A).